4.7 Article

Trans-anethole pretreatment ameliorates hepatic ischemia-reperfusion injury via regulation of soluble epoxide hydrolase

Journal

INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 124, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.intimp.2023.110809

Keywords

Liver ischemia and reperfusion injury; Trans-anethole; sEH; NLRP3 inflammasome

Ask authors/readers for more resources

Hepatic ischemia reperfusion injury (IRI) is a common complication in liver transplantation, and there is currently a lack of effective drugs for treatment. Trans-anethole (TA) is a compound with multiple effects that can alleviate liver IRI through anti-inflammation, anti-oxidative stress, and anti-apoptosis. This study confirms that TA pretreatment significantly improves liver function, reduces liver injury, inhibits hepatocyte apoptosis and inflammatory response, attenuates oxidative stress, and attenuates hepatic IRI by inhibiting NLRP3 inflammasome activation via regulation of soluble epoxide hydrolase (sEH).
Hepatic ischemia reperfusion injury (IRI) is a risk factor for early graft nonfunction and graft rejection after liver transplantation (LT). The process of liver IRI involves inflammatory response, oxidative stress, apoptosis and other pathophysiological processes. So far, there is still a lack of effective drugs to ameliorate liver IRI. Trans-anethole (TA) is an aromatic compound. Many medications as well as natural foods contain TA. TA has multi-ple effects such as anti-inflammation, anti-oxidative stress and anti-apoptosis. However, the mechanism of TA pretreatment in liver IRI is unclear. The mice hepatic IRI model was constructed after gavage pretreatment with TA (10 mg/kg, 20 mg/kg, 40 mg/kg) for 7 consecutive days. Our study confirmed that TA pretreatment significantly improve liver function and reduce serum AST, ALT in hepatic IRI. HE staining showed that TA pretreatment alleviated liver injury. Meanwhile, TA (20 mg/kg) pretreatment attenuated hepatocyte apoptosis in hepatic IRI. In addition, TA (20 mg/kg) pretreatment reduced the inflammatory factors TNF-alpha, IL-6 and infil-tration of CD11b positive cells in liver tissues during hepatic IRI in mice. TA pretreatment also alleviated oxidative stress in mice hepatic IRI. Our study further indicated that TA pretreatment attenuated mice hepatic IRI through inhibiting NLRP3 inflammasome activation via regulation of soluble epoxide hydrolase (sEH). This study provides a novel and effective potential drug with few side effects for easing liver IRI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available